

NAT & IGO joint meeting

Nantes, France - 28th & 29th May 2020

24th "Nantes Actualités en Transplantation" & 4th "LabEx IGO Meeting"

La Cité Nantes Congress Centre



New horizons in immunotherapy

This event is organised by:





Member research units:











In partnership with:

With the financial support of:













Chairwoman: Carole GUILLONNEAU – U1064 CRTI

Local organising committee:

Frédéric ALTARE - U1232 CRCINA Ignacio ANEGON - U1064 CRTI Sophie BROUARD - U1064 CRTI Yves DELNESTE - Cancéropôle Gra

Yves DELNESTE – Cancéropôle Grand Ouest

Giancarlo ESPEJO - LabEx IGO

Jean-François FONTENEAU - U1232 CRCINA Céline KERANDEL – ITUN U1064 CRTI Nathalie LABARRIERE - U1232 CRCINA Jérôme MARTIN - U1064 CRTI Catherine RABU – U1232 CRCINA Mikaël ROUSSEL – U1236 MICMAC Nina SKYBYK - NEXT I-Site University of Nantes Laurence WOLFF - LabEx IGO



NAT & IGO joint meeting

Nantes, France - 28th & 29th May 2020

DAY 1 - THURSDAY, MAY 28TH 2020

8:00 am	Registration & welcome coffee
8:45 am	Welcome Speech Carole Guillonneau, U1064 CRTI, Nantes

	SESSION I - ADVANCED CELL THERAPY
	Chairmen: Paolo Dellabona & Nathalie Labarrière
9:00 am	Reprogramming Human Immune Cells with CRISPR Alexander Marson, University of California, San Francisco, USA
9:30 am	Overcoming barriers to efficacy for engineered T cells in solid tumors Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA
10:00 am	CAR Tregs in transplantation and autoimmunity Ignacio Anegon, INSERM UMR 1064-Center for Research in Transplantation and Immunology, Labex Immunology Graft Oncology, FOCIS Center of Excellence Nantes University
10:30 am	Coffee break
11:00 am	Human tolerogenic dendritic cells used in clinic to regulate immune responses through lactate synthesis Aurélie Moreau, INSERM UMR 1064 - Center for Research in Transplantation and Immunology, University of Nantes / Nantes University Hospital, France
11:30 am	Selected communications

12:00 am Lunch break & Poster viewing session

	SESSION II - TISSUE MICROENVIRONMENT Chairmen: Barbara Seliger & Jérôme Martin
2:00 pm	Immunoregulation of inflammation Renato Monteiro, Center for Research on Inflammation - INSERM U1149 & CNRS ERL8252 / Paris Diderot Faculty of Medicine
2:30 pm	Evolution of a Stromal-Immune Axis in Cancer Immunology and Immunotherapy Shannon J. Turley, Department of Cancer Immunology, Genentech, South San Francisco, CA, USA
3:00 pm	TIGIT and its cellular and bacterial ligands: new checkpoints for cancer immune therapy Ofer Mandelboim, Institute of Medical Research Israel-Canada (IMRIC), University of Jerusalem, Israel
3:30 pm	Coffee break
4:00 pm	Myeloid cells and cancer immunotherapy Antonio Sica, Dept of Pharmacological Sciences, University of Eastern Piedmont, Novara / Head lab. Molecular Immunology, Humanitas Clinical and Research Center, Milan, Italy
4:30 pm	Immune escape mechanisms of tumors and their impact for immunotherapies Barbara Seliger, Institute for Medical Immunology at the Martin-Luther-University Halle-Wittenberg, Germany
5:00 pm	Selected communications

5:30 pm Cocktail & Poster viewing session



NAT & IGO joint meeting

Nantes, France - 28th & 29th May 2020

DAY 2 - FRIDAY MAY 29 TH 2020	
8:00 am	Coffee
8:30 am	Keynote speech - New immunotherapies in cancer and autoimmunity Jeffrey Bluestone, UCSF and Parker Foundation, USA
	SESSION III – BIOREAGENTS
	Chairmen: Hans-Dieter Volk & Carole Guillonneau
9:00 am	IL-2-based strategies targeting Tregs to stimulate or dampen the immune response Eliane Piaggio, Translational immunotherapy team U938, Institut Curie, Paris
9:30 am	Targeting Trained Immunity in Organ Transplantation Jordi Ochando, Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
10:00 am	Oncolytic activity of attenuated Measles virus and the defects in the type I interferon response in cancer - Jean-François Fonteneau, CRCINA (INSERM U1232), Nantes
10:30 am	Coffee break
11:00 am	Selected communications
11:30 am	Harnessing Innate Immunity in Cancer Therapy Eric Vivier, Aix Marseille University, APHM, CNRS, INSERM, CIML / Hôpital de la Timone, Marseille-Immunopole / Innate Pharma Research Laboratories, Marseille, France
12:00 am	Lunch break
	SESSION IV - NEW HORIZONS Chairmen: Megan Sykes & Catherine Rabu
1:30 pm	Targeting common epithelial malignancies with TCR engineered lymphocytes specific for 'public' neoantigens - Christopher Klebanoff, Memorial Sloan Kettering Cancer Center and the Parker Institute for Cancer Immunotherapy, New York, USA
2:00 pm	Presentation title tbc David Russell, Universal Cells, Inc., Seattle, USA
2:30 pm	Analysis of immune-epithelial cell interactions by Imaging Mass Cytometry Nicolas Damond, Department of Quantitative Biomedicine, University of Zurich, Switzerland
3:00 pm	Coffee break
3:30 pm	Mesenchymal stromal cell heterogeneity: implication for their clinical application Karin Tarte, Inserm U1236, University of Rennes, CHU Rennes, France
4:00 pm	Single Cell - Muzlifah Haniffa, Wellcome, Lister Institute, Newcastle Biomedical Research Centre, Institute of Cellular Medicine, Newcastle University, UK
4:30 pm	Awarding ceremony: best oral presentation, best poster